<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568281</url>
  </required_header>
  <id_info>
    <org_study_id>D539EC00001</org_study_id>
    <nct_id>NCT01568281</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Open Label, Single Centre, 2 Way Crossover Bioequivalence Study Comparing Arimidex Tablet 1 mg and Anastrozole Orally Rapid Disintegration Film Formula 1 mg After Single Oral Administration in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is to investigate whether anastrozole ODF is bioequivalent with Arimidex tablet
      after a single oral administration of each anastrozole formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomised, Open label, Single centre, 2 way Crossover Bioequivalence Study Comparing
      Arimidex Tablet 1 mg and Anastrozole Orally Rapid Disintegration Film Formula 1 mg After
      Single Oral Administration in Japanese Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigation whether anastrozole ODF is bioequivalent with Arimidex tablet.</measure>
    <time_frame>Blood samples are taken repeatedly for 24 hours and also taken occasionally up to 168 hours after each dose</time_frame>
    <description>By assessment of AUC and Cmax of anastrozole after a single oral administration of each anastrozole formulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetic properties of Arimidex tablet and anastrozole ODF following a single oral dose.</measure>
    <time_frame>Blood samples are taken repeatedly for 24 hours and also taken occasionally up to 168 hours after each dose</time_frame>
    <description>By assessment of AUC, MRT, tmax, kel and t1/2 of anastrozole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability of Anastrozole ODF 1 mg.</measure>
    <time_frame>Safety variables are measured prior to treatment and up to 14 to 17 days (follow-up) after the last dose. Subjects will be monitored throughout the study for adverse events</time_frame>
    <description>By assessment of adverse events, clinical laboratory tests, 12-lead ECG, blood pressure, pulse rate and body temperature.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Safety</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole ODF</intervention_name>
    <description>Each volunteer will receive a single dose of Anastrozole ODF with water.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimidex tablet</intervention_name>
    <description>Each volunteer will receive a single dose of Arimidex tablet with water</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole ODF</intervention_name>
    <description>Each volunteer will receive a single dose of Anastrozole ODF without water.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimidex tablet</intervention_name>
    <description>Each volunteer will receive a single dose of Arimidex tablet with water</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures Japanese healthy male subjects aged 20 to 45 years Male subjects should be
             willing to use barrier contraception ie, condoms, until 3 months after the last dose
             of investigational product Have a body mass index (BMI) between 18 and 27 kg/m2

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs Any clinically significant illness, medical/surgical procedure or trauma

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eisei Shin, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoko Matsuguma, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacology Research Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>anastrozole</keyword>
  <keyword>Arimidex</keyword>
  <keyword>Japanese</keyword>
  <keyword>healthy subject</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

